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Abstract 
Induced pluripotent stem cells (iPSc) have great potential for applications in 
regenerative medicine, disease modeling and basic research. Several methods have been 
developed for their derivation. The original method of Takahashi and Yamanaka 
involved the use of retroviral vectors which result in insertional mutagenesis, presence 
in the genome of potential oncogenes and effects of residual transgene expression on 
differentiation bias of each particular iPSc line. Other methods have been developed, 
using different viral vectors (adenovirus and Sendai virus), transient plasmid 
transfection, mRNA transduction, protein transduction and use of small molecules. 
However, these methods suffer from low efficiencies; can be extremely labor intensive, 
or both. An additional method makes use of the piggybac transposon, which has the 
advantage of inserting its payload into the host genome and being perfectly excised 
upon re-expression of the transposon transposase. Briefly, a policistronic cassette 
expressing Oct4, Sox2, Klf4 and C-Myc flanked by piggybac terminal repeats is 
delivered to the cells along with a plasmid transiently expressing piggybac transposase. 
Once reprogramming occurs, the cells are re-transfected with transposase and subclones 
free of tranposon integrations screened for. The procedure is therefore very labor 
intensive, requiring multiple manipulations and successive rounds of cloning and 
screening. 
The original method for reprogramming with the the PiggyBac transposon was 
created by Woltjen et al in 2009 (schematized here) and describes a process with which 
it is possible to obtain insert-free iPSc. Insert-free iPSc enables the establishment of 
better cellular models of iPS and adds a new level of security to the use of these cells in 
regenerative medicine. Due to the fact that it was based on several low efficiency steps, 
the overall efficiency of the method is very low (<1%). Moreover, the stochastic 
transfection, integration, excision and the inexistence of an active way of selection 
leaves this method in need of extensive characterization and screening of the final 
clones. 
In this work we aime to develop a non-integrative iPSc derivation system in 
which integration and excision of the transgenes can be controlled by simple media 
manipulations, avoiding labor intensive and potentially mutagenic procedures. To reach 
our goal we developed a two vector system which is simultaneously delivered to the 
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original population of fibroblasts. The first vector, Remo I, carries the reprogramming 
cassette and GFP under the regulation of a constitutive promoter (CAG). The second 
vector, Eneas, carries the piggybac transposase associated with an estrogen receptor 
fragment (ERT2), regulated in a TET-OFF fashion, and its equivalent reverse trans-
activator associated with a positive-negative selection cassette under a constitutive 
promoter. We tested its functionality in HEK 293T cells. 
The protocol is divided in two the following steps: 
1) Obtaining acceptable transfection efficiency into human fibroblasts. 
2) Testing the functionality of the construct 
3) Determining the ideal concentration of DOX for repressing mPB-ERT2 
expression 
4) Determining the ideal concentration of TM for transposition into the 
genome 
5) Determining the ideal Windows of no DOX/TM pulse for transposition 
into the genome 
6) 3, 4 and 5) for transposition out of the genome 
7) Determination of the ideal concentration of GCV for negative selection 
We successfully demonstrated that ENEAS behaved as expected in terms of 
DOX regulation of the expression of mPB-ERT2. We also demonstrated that by 
delivering the plasmid into 293T HEK cells and manipulating the levels of DOX and 
TM in the medium, we could obtain puromycin resistant lines. The number of 
puromycin resistant colonies obtained was significantly higher when DOX as absent, 
suggesting that the colonies resulted from transposition events. Presence of TM added 
an extra layer of regulation, albeit weaker. Our PCR analysis, while not a clean as 
would be desired, suggested that transposition was indeed occurring, although a 
background level of random integration could not be ruled out. Finally, our attempt to 
determine whether we could use GVC to select clones that had successfully mobilized 
PB out of the genome was unsuccessful. Unexpectedly, 293T HEK cells that had been 
transfected with ENEAS and selected for puromycin resistance were insensitive to GCV. 
Keywords: reprogramming, iPS, PiggyBac, transposon, transpositiono, cloning.  
__________________________________________________________Resumo 
vi 
 
Resumo 
Reprogramação celular é a tecnologia mais recente no campo da biologia celular 
e desenvolvimento. A possibilidade de reverter qualquer tipo celular a um estado de 
pluripotencia, a partir do qual possa ser diferenciado em qualquer outro do corpo 
humano, independentemente da célula de partida abriu toda uma panóplia de 
possibilidades e conceitos em Biomedicina. As propriedades intrínsecas das células iPS 
de divisão simétrica e pluripotencia, semelhantes às das células estaminais, tornam-se 
especialmente importantes para os ramos da medicina regenerativa e investigação 
biomédica, com realce para o desenvolvimento de modelos de doença in vitro, uma vez 
que contrariamente às células estaminais, só encontradas durante o desenvolvimento 
embrionário, as células iPS podem ser desenvolvidas a partir de um indivíduo adulto. 
Após obtenção de iPSs é possível obter virtualmente um número ilimitado de qualquer 
género celular do dador, inclusive células de difícil obtenção, por falta de casos, difícil 
isolamento, ou falta de casos clínicos. 
O método original foi desenvolvido por Takahashi e Yamanaka e baseia-se na 
administração e expressão forçada de factores de transcrição, nomeadamente Oct4, 
Sox2, Klf4 e C-Myc (OSKC). Estes factores foram referenciados ao longo dos anos por 
estudos de transcriptómica comparativa entre vários clones de células estaminais versus 
células conhecidas como percursoras, ou progenitoras, conhecidas por manterem ainda 
algum grau de pluripotencia, e células somáticas adultas. Em 1962, John Gurdon mudou 
todo o campo conhecido como biologia do desenvolvimento ao gerar clones de rã 
através de transferência nuclear somática (SCNT), provando que toda a informação 
genética necessária para formar o indivíduo adulto permanece no núcleo das células 
somáticas, despertando assim uma revolução na área e ao desenvolvimento do conceito 
de reprogramação celular. De referir também a contribuição marcante de Davis e 
colegas que em 1987, usando um elegante método de extracção de ADN complementar 
detectaram um conjunto de três genes que se encontravam predominantemente 
expressos em mioblastos. A transcrição forçada de apenas um desses genes, Myod1, 
revelou-se capaz de converter fibroblastos em mioblastos capazes de expressar miosina, 
relatando assim, pela primeira vez um processo actualmente denominado por 
reprogramação directa ou transdiferenciação. 
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Em relação ao processo de reprogramação propriamente dito, ainda há muito 
para descobrir. No entanto alguns mecanismos já foram deslindados nestes sete anos. 
Apesar de já serem conhecidas novas combinações de factores que são capazes de 
reverter o estado de diferenciação celular estabelecido em diferentes tipos celulares, os 
quatro factores de Yamanaka, OSKM continuam a ser o padrão na área, principalmente 
pela sua robustez e capacidade de reprogramar a maioria dos tipos celulares. Os factores 
OSKM têm um efeito sinergético, funcionando em conjunto para ultrapassar os 
resilientes sistemas celulares intrínsecos de protecção de identidade. Assim, neste 
sistema, a expressão de Oct4 e Sox2 promove maioritariamente um efeito 
desestabilizador da ordem transcripcional estabelecida, recrutando NANOG, outro 
agente de pluripotencia e formando um núcleo autoregulatório de pluripotencia. Este 
núcleo, uma vez estabelecido activa vias de sinalização como a via da MAPK1 e WNT3, 
e sinalizando o grupo Polycomb. Por outro lado, os factores Klf4 e c-Myc, como 
reguladores da divisão celular, têm uma actividade mitogénica, obrigando a alterações 
constantes no estado epigenético da célula, aumentando fortemente a cinética e 
eficiência do processo. 
Ainda que, ao momento, desenvolvimento de iPSs utilizando vectores virais 
integrativos de função semelhante aos utlizados na publicação original não seja já 
considerado um desafio a nível laboratorial, a transposição desses produtos para a 
investigação e aplicações clínicas tem sido problemático. Em primeiro lugar, existem 
evidências que na sua maioria, os clones de iPS mantêm algum nível de marcação 
epigenética reminiscente do tipo celular a partir do qual foram desenvolvidas; em 
segundo lugar, os métodos de entrega dos factores de reprogramação não integrativos 
são muito ineficientes, ao passo que os métodos integrativos induzem mutações 
insercionais, não sendo assim nem seguros nem desejáveis para aplicações clínicas; em 
terceiro e último lugar, desenvolvimento, expansão e caracterização de clones de iPS é 
um processo largamente moroso, lento e caro. 
Assim, torna-se evidente a necessidade imperiosa de desenvolvimento de 
protocolos de entrega de factores e reprogramação que permitam uma transposição 
segura para a clinica e garantam a aquisição de células de melhor qualidade para a 
investigação, garantindo a qualidade e confiança nos resultados. 
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Ao aliar a eficiência e reprodutibilidade dos métodos de reprogramação 
integrativos com a possibilidade de posterior excisão, os transposões, nomeadamente o 
PiggyBac, devido à sua ínfima taxa de mutação após excisão, surge como vector muito 
promissor para a administração de factores com vista à reprogramação celular. 
O presente trabalho surge neste contexto como uma contribuição para o 
desenvolvimento de um sistema de reprogramação baseado no transposão PiggyBac que 
seja simples e rápido, dispensando caracterização molecular após obtenção de iPSs. 
Por motivos de limitação de carga o sistema foi dividido em dois vectores a 
seres co-transfectados na população inicial de fibroblastos. O primeiro vector, Remo, é 
composto pela cassete de reprogramação contendo os factores OSKM e GFP sobre a 
expressão de um promotor constitutivo (CAG). O segundo vector, Eneas, é constituído 
pelo gene da transposase de codão optimizado para ratinho (mPB) associado a um 
receptor de estrogénio (ERT2) sobre a regulação de um sistema repressível por 
tetraciclina (TET-OFF). No extremo 3´ encontra-se ainda o transactivador reverso capaz 
de regular o promotor TET. Ambos os vectores contêm uma cassete de selecção 
positiva-negative e são flanqueados por sequências TR 5´ e 3´ específicas do transposão 
PiggyBac. 
 O protocolo consiste de duas partes: numa primeira instância, através de 
um pulso de expressão de mPB ambos os plasmídeos são transpostos para o genoma, 
permitindo expressão da cassete de reprogramação OSKM; posteriormente, após 
obtenção de colónias de iPSs, um segundo pulso seria imposto, de modo a permitir 
remobilização e obtenção de colónias iPS sem integração. Integração e mobilização 
serão controladas pela cassete de selecção positiva-negativa.  
 De modo a estabelecer o sistema os seguintes objectivos foram traçados: 
a) Clonar ENEAS; 
b) Escolha de um sistema de transfecção que permitisse altos níveis de 
transfecção em fibroblastos humanos. 
c) Testar a funcionalidade do sistema em termos de: 
a. Concentração de DOX necessária para reprimir a expressão 
de mPB; 
b. Concentração de TM ideal para transposição; 
c. Janela temporal de expressão de mPB; 
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d. Definir a, b e c para o processo de remobilização; 
e. Concentração ideal de GCV para selecção negativa. 
A clonagem do vector ENEAS foi lograda e confirmada por digestão com quatro 
enzimas distintas e posterior sequenciação. A funcionalidade de ENEAS foi testada em 
células HEK 293T. Por RT-PCR provou-se a repressão da expressão de mPB à 
concentração de 2 µg/ml de DOX. A concentração de TM foi titulada e confirmada quer 
pela bibliografia quer pelos testes de transposição com diferentes janelas temporais. 
Três janelas temporais de expressão de mPB foram testadas: 24H, 48h e 72h, revelando-
se a ultima a que melhores resultados gerava. 
Após obtenção de clones resistentes a puromicina, uma fracção dos mesmos 
foram expandidos sobre meio selectivo e quatro prosseguiram para caracterização por 
PCR genómico, de modo a averiguar se se tratavam de clones gerados por transposição 
catalisada por mPB. Apesar do surgimento de algumas dificuldades devido a 
amplificação de produtos de PCR na população controlo de 293T, as evidências 
apontam para que, ainda que nenhum dos quatro clones escolhidos tenha sido obtido 
apenas por transposição, diferentes intensidades de produtos de amplificação sugerem 
existência de transposição no sistema.  
Ainda que os resultados não tenham coincidido perfeitamente com o esperado, e 
uma nova bateria de testes tenha que ser desenhada de modo a aumentar o controlo 
sobre o sistema de transposição, provou-se a funcionalidade do sistema a nível 
molecular deixando esperança para que, em tempo, o conceito de concretize.  
 
Palavras chave: reprogramação, iPS, PiggyBac, transposão, transposição, 
clonagem. 
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1. Introduction 
Cellular reprogramming is widely considered a very promising field with great 
potential for regenerative medicine.  The possibility of generating a cell capable of 
making part of all the tissues of an adult body promises a new set of possibilities and 
strategies for biomedical research and regenerative medicine by enabling access to 
scarce cell types and theoretically autologous replacement. (Cherry and Daley 2012; 
Cahan and Daley 2013). 
Up to the beginning of the second half of the XX century, it was unknown 
whether differentiated cells had achieved their state by regulating a complete genome or 
if they had lost parts of their genome during specialization. In 1962, John Gurdon 
revolutionized the field of developmental biology by generating cloned frogs by somatic 
cell nuclear transfer (SCNT), proving, thus, that all genetic information needed to form 
an entire individual was still present in the differentiated cell and that, somehow, factors 
present in the oocyte cytoplasm were able to reverse the differentiated state off the 
somatic cell.  Regarding Waddington´s landscape, Gurdon´s findings would represent a 
movement uphill towards dedifferentiation (Gurdon 1962; Takahashi and Yamanaka 
2013; Turksen 2013).   
In 1987, Davis and colleagues, using an elegant method of complementary DNA 
extraction, detected a set of three genes that were predominantly expressed in myoblasts. 
Exogenous expression of one of those genes, Myod1, alone was sufficient to convert 
mouse fibroblasts to stable myosin-expressing myoblasts (Davis, Weintraub et al. 1987). 
This was the first report of transdifferentiation to be found in the literature. 
Contrasting with the previously described dedifferentiation, transdifferentiation refers to 
the direct conversion of one cell type into another without ever reaching the state of 
pluripotency. 
Based on the recent discoveries regarding cell reprogramming and cell fate 
imposition by a specific factor, Kazutoshi Takahashi and Shinya Yamanaka drew the 
experiment that would definitely change the paradigm of developmental biology and 
open a new set of possibilities for the fields of regenerative medicine and disease 
modeling. They selected a set of 24 genes that might have an effect on pluripotency, 
according with what was described for ES cell identity at that time, and screened it for 
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the minimal set of factors that enabled the reprogramming of adult fibroblasts into a 
pluripotent-like state when expressed ectopically. In this original study, exogenous 
expression of Oct4, Sox2, Klf4 and c-Myc (OSKM) were enough to reprogram mouse 
fibroblasts (Takahashi and Yamanaka 2006; Takahashi 2012; Warmflash, Arduini et al. 
2012; Takahashi and Yamanaka 2013). 
Although the iPS technology was only developed in 2006, the factors used in 
Yamanaka´s experiment had been known and associated with cellular pluripotency for 
some time. The study of gene expression associated with the formation of embryonic 
stem cells through microarray revealed a set of 230 genes with enhanced expression in 
stem cells relatively to somatic cells. Some of these  genes that had already been shown 
to participate in embryogenesis and ES formation, as well as the factors that would be 
used to reprogram mouse and human somatic cells (Ramalho-Santos, Yoon et al. 2002; 
Warmflash, Arduini et al. 2012). 
 
1.1   What happens during reprogramming? 
Embryonic stem cells are characterized by indefinite symmetric self-renewal and 
ability to differentiate into the three germ layers in vitro and in vivo. Somatic cells are, 
in turn, defined by a functional state of differentiation in which its identity and function 
are maintained by an internal lineage and type specific transcriptional and epigenetic 
status. These two levels of regulation function as a robust embedded system of 
protection to cell identity, avoiding undesired transdifferention and imposing a division 
limit, protecting against accumulation of mutations and development of malignancy in 
vivo.  
In order to reprogram somatic cells to a pluripotency state, several epigenetic 
and transcriptional roadblocks, specific of each cell type, must be overcome. 
Notwithstanding its robustness this mechanisms can now be surpassed by forced 
expression of key transcription factors, enabling the manipulation of cellular identity 
and cell fate. Ectopic expression of core pluripotency transcription factors like Oct4 and 
Sox2 has a dominant destabilizing effect over the existing transcriptional order, 
overruling the previous epigenetic and transcriptional state, and resulting in a stable 
phenotypic transformation to an embryonic-like state. Albeit is now current knowledge 
that reprogramming can still occur in absence of cell division, the co-expression of the 
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cell cycle regulator, Klf4 and c-Myc,  a mitogenic factor, along with Oct4 and Sox2, 
greatly enhances the overall efficiency of the process. Combined, these four factors 
cooperatively confer binding stability or specificity, most probably after the “pioneer” 
function of either Oct4 or Sox2 that recognizes their target sites independently of the 
previous chromatin state. Once established a stable transcription, the factors act in two 
main ways: on the one hand, Oct4 and Sox2 activate the expression of NANOG and 
form an autoregulated nucleus of pluripotency that enhances the expression of other 
pluripotency factors and paradoxically activates pro-differentiation pathways like 
MAPK1 and WNT3, and represses differentiation by activating the chromatin regulator 
Polycomb group (Cahan and Daley 2013); on the other hand, Klf4 and c-Myc activity as 
mitogens greatly enhances the kinetics of the process most likely by imposing 
epigenetic modifications inherent to cell division which probably opens a window of 
opportunity for the establishment of pluripotent-like epigenetic state, facilitating the 
process of reprogramming (Fig. 1) (Egli, Birkhoff et al. 2008; El-Karim, Hagos et al. 
2013). 
 
Fig. 1. Reprogramming with defined factors requires gradual replacement of ectopicly expressed factor with 
the endogenous circuitry of pluripotency. This process seems to be more efficient in rapidly dividing cells adapted 
from (Egli, Birkhoff et al. 2008). 
The whole process of reprogramming is still not fully known, which sustains 
many doubts regarding its future use in the biomedical field. Consequently, the 
scientific community designed a series of tests in order to access qualitatively which is 
the degree of a specific iPS clone. iPSC pluripotency was established in many ways. In 
order for a line to be classified as pluripotent it has to fulfill at least three of the 
following tests: a) ES-like gene expression and epigenetics; b) express extracellular 
markers of pluripotency, for example SSEA1; c) generate cells from the three germ 
layers in vitro or in vivo, d) participate in chimera formation and e) generate an embryo 
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by tetraploid complementation. Note that tests d) and e) cannot be performed in human 
iPS cells (Cherry and Daley 2012). 
Given the potential of this technology, the field has become a scientific hotspot 
of interest. One technology that is needed is a reproducible method that enables the 
development of an integration free iPS of clinical grade. Although recent reports claim 
to reach a reprogramming efficiency of virtually 100% (Rais, Zviran et al. 2013), within 
the premises of research, and due to its simplicity and robustness, integrative methods, 
mostly viral vectors similar to the ones used by Yamanaka are still the most common 
(Egli, Birkhoff et al. 2008; Yamanaka 2012; El-Karim, Hagos et al. 2013; Takahashi 
and Yamanaka 2013; Turksen 2013). 
1.2. Use of induced pluripotent stem cells in 
Regenerative medicine: 
Induced pluripotent stem cells derivation in humans was first reported by 
Takahashi and Yamanaka in 2007 (Takahashi, Tanabe et al. 2007) and immediately 
recognized as a landmark breakthrough, extending Gurdon´s reversibility of 
development. Their basic result was that adult somatic cells were able to undergo a 
phenotypic makeover by retrovirus mediated over-expression of 4 transcription factors 
(Oct4, Sox2, Klf4 and c-Myc) resulting in embryonic stem cells like colonies 
(Yamanaka and Blau). Alike the already known mouse iPS cells, these cells were also 
found to self-renewal and differentiate in the three germ layers i.e., pluripotency. Since 
then, a number of methods for direct reprogramming have been developed and some 
basic characteristics of the reprogramming mechanism established (Hanna, Saha et al. ; 
Jaenisch and Young 2008; Marson, Levine et al. 2008; Gonzalez, Boue et al. 2011).   
Although so far, all the attempts to generate functional specialized cells from 
embryonic stem (ES) cells have not been entirely successful, there is still the belief that 
a more comprehensive understanding of cellular identity and specific cellular niches 
would allow its in vitro reproduction with good results. Nevertheless, there are some 
experiments with mouse ES cells that have already been partly successful, as is the case 
of mouse blood cells, pancreatic cells and specialized neurons (Cherry and Daley 2012). 
Taking on these principles and, because environmental influences and epigenomic 
specificities are mostly erase through long passaging of iPS clones bringing these cells 
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even closer to ES cells, it is expectable that, in time, patient specific tissues could be 
derived, enabling , autologous transplantations of in vitro differentiated cells, thus 
avoiding the now necessary use of immune suppressors. Furthermore, in order to avoid 
resurgence of genetic diseases, homologous recombination of iPS clones could be an 
option, as proved with the correction of sickle-cell anemia in mouse (Tiscornia, Vivas et 
al. 2011; Robinton and Daley 2012). 
From the point in which we stand, two general approaches can be followed in 
the future in order to restore a missing tissue or cell type: a) derivation of iPS cells from 
an easy accessible tissue (for example skin or blood), followed by ex vivo differentiation 
of the desired cell type which would be transplanted and integrated in the desired organ; 
b) direct conversion of somatic cells into the progenitor cell of the desired cell, thus 
creating a population that would affect cell regeneration in situ rather than directly 
replacing it. Although these two hypotheses may promise novel medical approaches to 
several diseases, the existing methods of reprogramming are still not able of creating 
clinical grade iPSC in a consistent and reproducible way on a clinically relevant amount 
of time (Cherry and Daley 2012).  
1.3. Use of induced pluripotent stem cells in Disease 
modeling: 
The study of human disease in the lab has been limited to studying human cells 
in vitro or developing animal models of the condition. Human tissue is usually 
relatively difficult to access, and often, the accessible cell types are not of interest to the 
disease, limiting the experimental approaches. While animal models have provided 
powerful experimental systems and allow studies at the organismal and systemic level, 
they suffer from the intrinsic disadvantage of not being human (Tiscornia, Vivas et al. 
2011). The development of murine models tends to be slow and in most cases have been 
shown not to reproduce the human phenotype faithfully and there is growing realization 
that a high number of therapies developed in animal models fail in clinical trials (van 
der Worp, Howells et al. 2010). Perfect example of that is the case of amyotrophic 
lateral sclerosis and Gaucher´s Disease, in which the animal model may not always 
recapitulate exactly the human form of the disease, resulting in an active drug in mouse 
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but rather innocuous in the human case (Farfel-Becker, Vitner et al. 2011; Wu and 
Hochedlinger 2011).  
Along with their potential for regenerative medicine applications, direct 
reprogramming offers an alternative paradigm for studying human disease: patient 
specific cells can be reprogrammed, characterized and differentiated to the disease 
relevant cell type. Thus, large amounts of relevant cell types carrying specific human 
disease causing mutations can be generated in culture for investigating basic pathogenic 
mechanism, hypothesis testing, toxicology studies, pharmacological compound 
screening and development of novel therapeutic approaches. In the few years, this 
approach has been demonstrated successfully for a number of diseases, including, 
including ALS, SMA , Rhett Syndrome, Long QT Syndrome, Pompe’s Disease and 
others (Dimos, Rodolfa et al. 2008; Ebert, Yu et al. 2009; Marchetto, Carromeu et al. 
2010; Huang, Chen et al. 2011; Itzhaki, Maizels et al. 2011; Tiscornia, Vivas et al. 
2011). These encouraging new results demonstrated that the iPS technology makes a 
good target for modeling monogenic and multigenic diseases, creating the possibility of 
high throughput pharmaceutical analysis, settle the basis for a pharmacogenomics based 
medicine. 
1.4. Methods of reprogramming: 
Over the years, with the development of the field and the increased knowledge 
on reprogrammed cell behavior, scientists have been pushing forward towards the 
development and practical use of these cells in biomedicine. For iPSc to be used in 
regenerative medicine, issues of differentiation, genetic instability and ultimately the 
risk for tumorigenicity must be addressed. The classic method of reprogramming using 
retroviral vectors, though practical, is unsuited to clinical practice.  Moreover, although 
the retroviral vectors stay mostly repressed in immature cells like, as is the case of iPSc, 
when differentiated, these cells might reactivate those inserts, acting as a counter 
stimulus to the differentiation process decreasing the final yield of the process, 
preventing in some cases a stable maintenance of the differentiated phenotype and 
producing an heterogeneous population in various states of differentiation. Likewise, 
cell culture and maturation protocols must be optimized. Until now, maintaining 
pluripotent cells and differentiating was a long, complicated and expensive process, 
which in most of the cases did not guarantee a high percentage of the desired cell type 
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or state of maturation, requiring several rounds of optimization for each tissue and 
organism, in order to maximize the yield, quality and thus, in vivo integration. Finally, 
in the case of disease modeling, some genetic diseases need crucial environment in 
order to develop is characteristic phenotype. Fulfilling these requisites will mark the 
next step forward in the pluripotency field (González, Boué et al. 2011; Vierbuchen and 
Wernig 2012). 
Since the publication of the first method of reprogramming by retroviral delivery 
a broad number of new methods and approaches to induce pluripotency in somatic cells 
have been developed. Alongside with these new techniques a standard array of testes 
has been defined in order to properly address the contribution and improvement that 
each method brings onto the field. 
As reference before, there are two major research applications when considering 
the iPS field: the first one is more directed to the basic research fields, focusing on 
deciphering the mechanisms of reprogramming, differentiation and cell identity and a 
second one, is more direct towards relevant clinical applications and iPS based therapies. 
For the present being, a reprogramming strategy that fits all the purposes and ends of 
application for the field has still not been designed. So, instead, we have an array of 
strategies that can be used, depending on the final application to obtain a useful iPS 
population.  
In the first case, when clinical grade cells are not required, but rather a fast, 
efficient and reproducible method is desired, and the presence of foreign DNA or 
expression of possible tumorigenic factor is tolerable, as is the case of the study of 
mechanisms of disease and the development of models of disease for drug testing, the 
use of integrative inducible lentiviruses provides efficient and robust results. In the 
second case, on the other hand, when clinical applications are considered and avoidance 
of genomic modifications is strictly necessary for safety reasons. Thus, non-integrative 
methods represent, until now, the only reasonable option.  Non-integrative methods can 
be divided into four fundamental categories: episomal delivery, RNA delivery, protein 
delivery, integration-defective viral delivery. Despite the fact that these approaches are 
theoretically safe, they are difficult to apply, due to poor transfection efficiencies, cell 
survival, long reprogramming kinetics and possibly other unknown limitations which 
result in high inefficiency and poor reproducibility (González, Boué et al. 2011). 
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In this context of need for a high efficiency method that preserves the original 
genomic sequence, transposable systems, may be good candidates as factor delivery 
vectors, due to their merged characteristics of integrative vector, with stable expression 
and relatively high reprogramming efficiency, along with the possibility of being later 
excised from the genome. Within the several transposons known to transpose in 
mammal cells, most belong to either the TC1 family, like Sleeping Beauty; the hAT-like 
Tol2; Frog Prince, or to the PiggyBac superfamily. The PiggyBac transposon was first 
isolated from cabbage looper moth Trichoplusia ni in 1989. Nevertheless, only recently 
has emerged as a reliable tool in molecular biology for cargo delivery and insertional 
mutagenesis, quickly becoming the option of choice due to its cargo capacity, absence 
of transposase overexpression repression and, most of all, its perfect cut and paste 
mobilization, restituting the original sequence in over 98% after remobilization (Fig. 2) 
(Li, Pettitt et al. 2013).  The first iPSCs reprogrammed with a PiggyBac transposon 
were obtained by Woltjen et al in 2009. Derivation insert-free iPSc enables the 
establishment of better cellular models of iPS and adds a new level of security to the use 
of these cells in biomedical applications. Nevertheless, due to the fact that it was based 
on several low efficiency steps consisting of consecutive transfections, with plasmid 
dilution overtime resulted in an overall low efficiency. Moreover, the constant 
possibility of random integration forces a molecular characterization of each clone, 
which ended up being laborious, time demanding and expensive (Kim and Pyykko 
2011). 
 
Fig. 2. Model of PB cut and paste mobilization from a plasmid. PB transposase recognizes and integrates 
into TTAA sequences with preference for euchromatin regions. Adapted from (Li, Pettitt et al. 2013).  
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1.5. Objectives 
The objective of the present work is to provide an improved and simplified 
PiggyBac system for reprogramming. We developed a two vector system which is 
simultaneously delivered to the original population of fibroblasts. The first vector, Remo, 
carries the reprogramming cassette and GFP under the regulation of a constitutive 
promoter (CAG). The second vector, Eneas, carries the piggyback mouse transposase 
(mPB) associated with an estrogen receptor fragment (ERT2), regulated in a Tetracyclin 
repressible (TET-OFF) fashion, and its equivalent reverse trans-activator associated 
with a positive-negative selection cassette under a constitutive promoter. Both 
constructs carry a positive-negative selection cassette and are flanked by the PiggyBac 
5´ and 3´terminal repeats. This method is designed to be time and work efficient, 
hopefully resulting in insert-free iPSc within six weeks. The protocol is divided in two 
parts: first, through expression pulse of mPB, both Remo and Eneas get transposed into 
the genome, allowing expression of the OSKM in a stable manner; secondly, after 
obtaining iPSCs a second pulse of mPB expression will remobilize the inserts, resulting 
insert-free iPSCs. Integration and remobilization will be controlled recurring to the 
positive negative selection of PuroTk positive-negative marker, being that, during the 
first pulse of mPB expression, cells carrying the insert will become puromycin resistant 
and after the second pulse, only cells that have lost all the insert will be resistant to 
ganciclovir. Ultimately, iPS derivation will be achieved simply by controlling the media 
without the need for clonal expansion and further characterization. This transposable 
system would, in theory, work the following way: 
1) A plasmid containing a piggyback transposon would be delivered to the cells to 
be reprogrammed. 
2) The transposon would contain the following genetic elements: 
a) A policystronic reprograming cassette composed of human Oct4, Sox2, 
Klf4, c-Myc and GFP linked by 2A self-cleaving peptides driven by a 
constitutive CAG promoter. 
b) A constitutive PGK promoter driving a tTA transactivator (TET-OFF 
system), followed by an IRES element and a PuTK gene fusion for positive-
negative selection. 
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c) A TET responsive CMV minimal promoter expressing mPB transposase 
linked to a tamoxifen inducible nuclear translocation ERT2 element. 
d) Elements a, b and c would be flanked by transposon TR. 
After transfection, the cells would be subjected to a limited pulse of no DOX and 
TM. PGK would constitutively express the tTA protein. During the windows of no 
DOX/TM treatment, the absence of DOX would cause the tTA protein to activate 
expression of mPB-ERT2. TM would induce translocation of the mPB-ERT2 protein to 
the nucleus, where it would catalyze transposition of the transposon into the host 
genome. The transposition pulse would be terminated by adding DOX and withholding 
TM from the medium. Theoretically, the remainder of the plasmid backbone would be 
lost by dilution. Constitutive expression of the reprogramming cassette would result in 
iPSc colony formation. These colonies would constitutively express both puromycin 
resistance (positive selection marker) and TK (negative selection marker). As iPSc 
reprogramming is in itself a selective event, puromycin selection would be unnecessary. 
Once the iPSc line was obtained, it would be subject to a second pulse of DOX/TM, 
which would result in re-expression of mPB-ERT2, translocation to the nucleus and 
excisional transposition of PB out of the genome. As this event can result in either 
permanent excision or reinsertion into the genome, the cells would be selected with 
ganciclovir for clones having lost the transposon and therefore no longer expressing the 
PuTK fusion. Therefore, an integration free iPSc line would result. Fine tuning of the 
system would require: 
8) Obtaining acceptable transfection efficiency into human fibroblasts. 
9) Testing the functionality of the construct 
10) Determining the ideal concentration of DOX for repressing mPB-ERT2 
expression 
11) Determining the ideal concentration of TM for transposition into the 
genome 
12) Determining the ideal Windows of no DOX/TM pulse for transposition 
into the genome 
13) 3, 4 and 5) for transposition out of the genome 
14) Determination of the ideal concentration of GCV for negative selection 
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An initial problem with the system was that the cargo of genetic elements 
required for the strategy (approximately 16 kb) was well over the carrying capacity of 
the PB transposon (approximately 8 kb). If cargo exceeds the PB carrying capacity, 
transposition efficiency drops markedly. Therefore, a two PB system was designed: One 
transposon would deliver the reprogramming cassette while the second would deliver 
the TET-OFF system and the mPB-ERT2 elements. Both transposons would express the 
PuTK positive/negative selection elements. Hence, the strategy would involve delivery 
of two transposons, induction of transposition, reprogramming, induction of excision 
and finally selection for ganciclovir resistant clones. 
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2. Materials and Methods 
2.1. Cloning of EneasI 
This system was designed to work with 5´PTK3´TETO-CMV-mPB-L3ERT2-
hPGK-tTA hereby known as ENEAS in association with a 5´CAG-OSKM-GFP 3´, 
hereby REMO I. Partial construction of ENEAS had advanced to an intermediate stage 
where the only element missing was the TRE-CMV-mPB-ERT2 cassette. This cassette 
had been previously constructed (plasmid pCR BT TETO CMV-mPB-ERT2).  
To conclude the cloning of ENEAS the following steps were taken, as 
schematized on Fig.3, and described next. The TRE-CMV-mPB-ERT2 cassette was 
excised from the plasmid pCR BT TETO CMV-mPB-ERT2 by digestion with 
restriction enzymes NHeI and ClaI. The recipient vector was digested with NheI and 
ClaI and then treated with CIP to prevent concatemerization. Both fragments were 
ligated using T4 DNA ligase and transformed into elctrocompetent bacteria which were 
then selected in LB agar with ampicillin (1µg/mL). Plasmid DNA was extracted from 
18 ampicillin resistant colonies and analyzed by restriction digest with BamHI, HindIII 
and NcoI. All the reagents were commercially acquired from New England Biolabs. 
 
Fig. 3. Experimental setup of ENEAS cloning procedure. First both plasmids were digested with NheI and 
ClaI: 1 and 4- double digestion; 2-3 and 4-6 -single digestion controls (On the top). Secondly, both isolated insert and 
destination vector were ligated using T4 ligase (midle). Finally, the ligation reaction was electroporated into SURE 
cells which were selected for ampicillin resistance. 
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2.2 Characterization of ENEAS 
In order to test the functionality of the system and determine if the construct 
functions as predicted and fine tune it accordingly with the objectives, i.e., obtain an 
integration efficiency that maximizes the number of insert bearing cells with minimal 
number of individual integrations which would enable an optimal loss of integration 
thoµgh mobilization, thus maximizing the efficiency of the system. As a matter of 
practicality the tests were performed in 293T HEK cells with a passage number inferior 
to 20. The first part of the characterization (1) is designed to guarantee the 
responsiveness of the system to DOX, TM, evaluate the ability to generate Puromycin 
resistant colonies in different conditions. In a second phase (2), the obtained clones 
were physically isolated and expanded in order to determine the conditions of 
remobilization, and selection with GcV. Fine tuning was performed using the following 
tests: 
A. Obtaining acceptable transfection efficiency and test the functionality of the 
construct 
1) Determining the ideal concentration of DOX for repressing mPB-
ERT2 expression 
2) Determining the ideal concentration of TM for transposition into the 
genome 
3) Determining the ideal Windows of no DOX/TM pulse for 
transposition into the genome 
B. Fine tuning transposon excision: 
1) Clonal expansion of puro resistant clones and diagnostic genomic 
PCR 
2) Repeat tests A1, A2 and A3 for excision 
3) Determining the ideal concentration of GcV for negative selection. 
A. Fine tuning of integration and working conditions 
Initially, we determined the minimal amount of puromycin concentration 
required to kill at least 50% of non-transfected 293T cells. To do so, 500,000 293T cells 
were seeded in a 10 cm tissue culture dish and subjected increasing concentrations of 
puromycin (0, 250, 500, 1000 and 2000 µg/ml). Cells were observed for 10 days. Cells 
subjected to no puromycin or 250µg/ml puromycin continued to grow and achieved 
confluency after 5 days. A concentration of 250 µg/ml resulted in aproximately 80% 
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cell death, while higher concentrations of puromycin obliterated the whole cell 
population. Therefore, we chose 500µg/ml as our puromycin selection concentration. 
1) Determining the ideal concentration of DOX for repressing mPB-ERT2 
expression 
 
 We set up a series of experiments with the goal of determining the correct 
procedure to obtain transposition of PB into the genome of our target cells. Proceeding 
by trial and error, after a few attempts we determined that the following procedure 
should be followed: 
1) Seed 200,000 293T cells in a 35 mm dish, incubate overnight 
2) Next morning add the appropriate amount of DOX (0, 2 and 10 µg/ml) 
and TM (1 µM) to each well 
3) After six hours of pre-incubation in DOX/TM conditions, transfect 
100ng of ENEAS into each dish, using Fugene6 (promega), following 
given protocol. 
4) Maintain the conditions for 72 hs 
5) Add DOX and eliminate TM (+DOX/-TM) from all dishes in order to 
repress further transposition 
6) Trypsinize and passage the cells into 10 cm dishes, maintain +DOX/-TM 
conditions and select for puromycin resistance with 500 ng/ml. 
7) Harvest the cells and Proceed to RT-PCR. 
RT-PCR 
The total RNA of each of the conditions 0, 2 and 10 µg/ml of DOX was 
extracted using the Trizol protocol for RNA extraction and retro-transcribed into cDNA 
using random hexamers as primers. Once obtained, the cDNA served as a PCR template 
for two sets of primers in order to amplify two fragments: an ERT2 region of 300bp and 
a fragment of the transactivator (tTA). Both PCRs were catalyzed by a Go Taq 
polymerase (promega), using the brand suggested cycling conditions with a melting 
temperature of 57ºC and 35 cycles. 
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2) Determining the ideal concentration of TM for transposition into the 
genome 
To evaluate the effect of TM in transcriptionally active clones we designed the 
following experiment: 
1)  Seed 200,000 293T cells in a 35 mm dish, incubate overnight 
2) Next morning add the appropriate amount of TM (0,25µM, 0,5µM, 1mM 
and 1,5mM) to each well 
3) After six hours of pre-incubation in DOX/TM conditions, transfect 
100ng of ENEAS into each dish, using Fugene6 (promega), following 
given protocol. 
4) Maintain the conditions for 72 hs 
5) Add DOX and eliminate TM (+DOX/-TM) from all dishes in order to 
repress further transposition 
6) Trypsinize and passage the cells into 10 cm dishes, maintain +DOX/-TM 
conditions and select for puromycin resistance with 500 ng/ml. 
7) Proceed to crystal violet (CV) coloration.  
a. Wash carefully the colonies with PBS; 
b. Fixate cells for 1 min with 4% PFA; 
c. Remove PFA and add 0.1% CV solution for 30 minutes ; 
d. Remove CV and wash with tap water. 
 
3) Determining the ideal Windows of no DOX/TM pulse for transposition into 
the genome 
Having both the DOX and TM titrated to working concentrations, we tried to 
determine the mPB expression pulse that would result in consecutive appearance of 
colonies consistent with what was expected. Three expression windows were tested: 
24h, 48h and 72h. Although colonies were evident in all time points, the 72h window 
rendered more consistent and evident differences, being repeated five times with similar 
outcomes. Following the outline of the previous experiments, a set of conditions, was 
created base on table 1. 
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Table 1. Set of conditions used to optimize the window of expression for ENEAS transposition. 
 
The procedure was the following: 
1) Seed 200,000 293T cells in a 35 mm dish, incubate overnight 
2) Next morning add the appropriate amount of DOX and TM (table 1) to 
each well 
3) After six hours of pre-incubation in DOX/TM conditions, transfect 
100ng of ENEAS into each dish, using Fugene6 (promega), following 
given protocol. 
4) Maintain the conditions for 72 hs 
5) Add DOX and eliminate TM (+DOX/-TM) from all dishes in order to 
repress further transposition 
6) Trypsinize and passage the cells into 10 cm dishes, maintain +DOX/-TM 
conditions and select for puromycin resistance with 500 ng/ml. 
7) Proceed to crystal violet (CV) coloration.  
a. Wash carefully the colonies with PBS; 
b. Fixate cells for 1 min with 4% PFA; 
c. Remove PFA and add 0.1% CV solution for 30 minutes ; 
Remove CV and wash with tap water 
B. Fine tuning transposon excision 
After establishing all the previous parameters and be able to consistently 
reproduce the same result, consisting with the theoretic prevision, the protocol A-3 was 
once again repeated. Instead of proceeding to CV coloration, 12 individual clones were 
physically isolated and expanded.  
1) Clonal expansion of puro resistant clones and diagnostic genomic PCR 
The isolated clones were kept under puro selection (500ng/ml) and DOX repression 
(2µg/ml) for two passages and then frozen in complete DMEM+ 10% DMSO. Genomic 
DNA was extracted from four of the puro resistant clones, using a Quiagen QIAamp 
DNA Mini Kit. Samples were tested for integration by PCR, using a KAPATaq hotstart 
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polymerase (from KAPABIOSYSTEMS). The reaction was setup as described in table 
2, using the commercial cycling parameters with a melting temperature of 52ºC and 35 
cycles. The resulting PCR products were ran in a 2% agarose gel and images were 
acquired using a Chemidoc imaging system (BioRad). 
Table 2. KAPATaq PCR setup 
.
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3. Results 
This sytem had been already partially designed and constructed before the 
comencement of this project. The PB transposon carrying the reprogramming cassette 
and the rtTA-IRES-PuTK elements (called Romulus) had already been completed (see 
fig 4). The second PB transposon, carrying the mPB-ERT2 and the rtTA-IRES-PuTK 
elements (called ENEAS) was partially constructed. The first task of this project was to 
complete the cloning of ENEAS. 
 
Fig. 4. Schematic representation of Romulus. 
 
3.1. Cloning of ENEAS: 
The cloning strategy is illustrated in Fig 3. Partial construction of ENEAS had 
advanced to an intermediate stage where the only element missing was the TRE-CMV-
mPB-ERT2 cassette. This cassette had been previously constructed (plasmid pCR BT 
TETO CMV-mPB-ERT2), Fig.5. Therefore, the TRE-CMV-mPB-ERT2 cassette was 
excised from the plasmid pCR BT TETO CMV-mPB-ERT2 by digestion with 
restriction enzymes NHeI and ClaI and gel purified. The recipient vector was similarly 
digested with NheI and ClaI and gel purified. Both DNA fragments were ligate using T4 
DNA ligase and transformed into elctrocompetent bacteria. Plasmid DNA was extracted 
from a number of ampicillin resistant colonies and analyzed by restriction digest with 
HindIII (fig.6A). Several clones with the expected restriction fragment pattern were 
obtained. One particular cloned was amplified and further analyzed by additional 
restriction digest analysis (fig. 6B) and confirmed by sequencing to have the correct 
sequence in all genetic elements (data not shown).  
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Fig. 5. Schematic representation of the genetic constructs used to clone ENEAS (A and B) and ENEAS (C). 
In C we can also observe the expected restriction fragments of a restriction with HindIII (8,2Kb and 2,6Kb). 
 
 
Fig. 6. A: Restriction digest of the 18 ENEAS clones with HindIII. Seven of the 18 clones presented the 
expected band of 2,5Kb. The  marked clones were expanded and saved for further analysis.. B:Diagnostic restriction, 
cuts of Eneas with BamHI (B), HindIII (H) and NcoI (N). All the bands correspond to the expected sizes: B- 5,47Kb, 
3,36Kb 1,19Kb and 0,796Kb; H- 8,22Kb and 2,Kb; N- 8,6Kb, 1,39Kb and 0,798Kb. 
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3.2. Characterization of ENEAS 
Is the mPB-ERT2 cassette expression responsive to DOX? 
We next sought to determine whether ENEAs would work as predicted. In a first 
step, we asked whether mPB-ERT2 expression could be controlled by manipulating the 
levels of DOX in the medium. To do so, we transiently transfected ENEAS plasmid into 
293T cells using the Fugene6 transfection reagent (Roche) and cultured the cells for 72 
hs in absence of DOX and in two concentrations of DOX (2 µg/ml and 10 µg/ml). Cells 
were washed, harvested and extracted for total RNA, which was then analysed by RT-
PCR. 
The results of the analysis (see Fig 7), indicated that strong expression of mPB-
ERT2 was obsevable in absence of DOX, while strong repression of expression was 
obtained with both DOX concentrations used. In contrast, and as expected, constitutive 
expression of tTA was unaffected by presence of absence of DOX in the media. 
Furthemore, we confirmed that the mPB-ERT2 band observed in absence of DOX (300 
bp)indeed represented the correct sequence, as digestion with HindIII restriction 
enzyme yeilded 2 bands of the expected length (176 bp and 124 bp). 
 
Fig. 7.Panel showing the transcriptional analysis of ENEAS in 293T HEK cells through amplification of na 
ERT sequence (Aand B) in order to check repression by DOX, and  amplification of a tTA to confirm constitutive 
expression of the transactivatior. The amplification o ERT was repetad as in A. The sample (b) was run against a 
control (a) of picture B, and simultaneously cut with HindIII to confirm identity of the amplicon (picture D). A- the 
control (a) of 293T cells without transfection of ENEAS was run against ENEAS clones without any DOX in the 
media (b), and respectively, with 2 and 10 µg/ml of DOX (c and d). C- expression of the tTa sequence was compared 
between a non-transfected 293T HEK population (b) with transfected cells without DOX (a), with 2 and 10 µg/ml of 
DOX (c and d). In the gels A, B and C a 1Kb ladder was used, whereas in D, due to to the small size of the digestion 
products, a 100bp ladder was used. 
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3.2.1 Does ENEAS function as expected in an in vitro cell transfection 
experiment? 
We sought to establish the parameters for correct functioning of ENEAS for 
obtaining transposon containing colonies of cells. For reasons of practicality, we chose 
to work with 293T HEK cells. If ENEAS worked as designed, when transfected into 
cells its behavior should depend on the presence or absence of DOX in the medium. In 
absence of DOX (but presence of TM), PB should transpose into the genome of 
recipient cells and create puromycin resistant clones. In contrast, in the presence of 
DOX (and presence of TM), the mPB-ERT2 cassette should not be expressed and 
therefore transposition should not occur and puromycin resistant colonies should not be 
obtained.   
Initially, we determined the minimal amount of puromycin concentration 
required to kill at least 50% of non-transfected 293T cells. To do so, 500,000 293T cells 
were seeded in a 10 cm tissue culture dish and subjected increasing concentrations of 
puromycin (0, 250, 500, 1000 and 2000 µg/ml). Cell were observed for 10 days. Cells 
subjected to no puromycin or 250 µg/ml puromycin continued to grow and achieved 
confluency after 5 days. A concentration of 250 µg/ml resulted in aproximately 80% 
cell death, while higher concentrations of puromycin obliterated the whole cell 
population. Therefore, we chose 500 µg/ml as our puromycin selection concentration. 
We set up a series of experiments with the goal of determining the correct 
procedure to obtain transposition of PB into the genome of our target cells. Proceeding 
by trial and error, after a few attempts we determined that the following procedure 
should be followed: 
1) Seed 200,000 293T cells in a 35 mm dish, incubate overnight 
2) Next morning add the appropriate amount of DOX (0, 2 and 10 µg/ml) and 
TM (1 mM) to each well 
3) After six hours of pre-incubation in DOX/TM conditions, transfect 100 ng of 
ENEAS into each dish 
4) Maintain the conditions for 72 hs 
5) Add DOX and eliminate TM (+DOX/-TM) from all dishes in order to repress 
further transposition 
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6) Trypsinize and passage the cells into 10 cm dishes, maintain +DOX/-TM 
conditions and select for puromycin resistance with 500 µg/ml. 
After 2 weeks of puromycin selection, puromycin resistant colonies were aparent 
and styained with crystal violet. Results of a typical experiment are shown (Fig 8): 
 
Fig. 8. Crystal violet coloration of Puro resistant colonies of 293T cells transfected with Eneas (100ng). 
Dox titration to shutdown mPB expression. 1- No Dox no Eneas; 2- Eneas no Dox; 3- Eneas+ Dox 2µg/mL; 4- Eneas 
+ Dox 10 µg/mL; 5- Eneas + Dox 20 µg/mL. 
As shown in Fig.8, the system behaved reasonably as expected. When ENEAS 
was transfected into 293T HEK cells and the cells subjected to a 72 hr window in 
absence of DOX and presence of TM, a number of puromycin resistant clones appeared 
in the dish. However, if 2 or 10 µg/ml of DOX were added to the medium during the 72 
hr window, the number of puromycin resistant colonies droped significantly, although 
not to zero. These results showed that overall, the system seemed to be working as 
expected, and that the number of colonies correlated with the presence or absence of 
DOX in the culture medium. This result led us to bilieve that the colonies that were 
appearing in absence of DOX were due to transposition events. 
3.2.2. What is the effect of TM on the system? 
In our strategy, the levels of transposition are designed to be controlled by two 
parameters: the level of DOX in the culture medium (which would determine the level 
of expression of mPB-ERT2) and the presence or absence of TM (which would enhance 
the cytoplasmic-nuclear transport of mPB through interaction with the ERT2 domain of 
the fusion protein. The experiment described in the previous section was conducted in 
the presence of TM, ie, in conditions that maximized the translocation into the nucelus 
of whatever amount of mPB-ERT2 was being expressed. We then asked what were the 
relative contributions of each of the two levels of control. To determine this, we set up 
the following experiment: 
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Well #1: ENEAS not transfected 
Well #2: ENEAS transfected, 0 µg/ml DOX, no TM 
Well #3: ENEAS transfected, 2 µg/ml DOX, no TM 
Well #4: ENEAS transfected, 0 µg/ml DOX, 1mM TM 
Well #5: ENEAS transfected, 2 µg/ml DOX, 1mM TM 
As before, the number of puromycin resistant colonies surviving after two weeks 
of puromycin selection was scored by crystal violet staining. The results are shown in 
Fig 9.  
 
Fig. 9. Crystal violet coloration of colonies obtained after the selection with puromycin (puro) of the 72h 
expression window. Number 1 represents the negative control, consisting of a 293T HEK population treated with 
puro. Numbers 2 through 5 represent populations transfected with ENEAS (100ng) and treated with the following 
conditions: 2- no DOX and no TM; 3- Dox without TM; 4- TM without DOX; and 5- DOX and TM. The 
concentrations were for DOX 2µg/ml and 1mM for TM. 
The overall number of violet colonies (overall 'violetness' of the dishes) provides 
a semiquantitative measure of transposition efficiency. The results suggest that in 
absence of TM in the medium, most of the regulation is afforded by the presence or 
absence of DOX in the culture medium, while adding TM enhances the level of 
transposition generally, but not by a large amount.  
Are the puromycin resistant clones obtained due to transposition events or random 
integration? 
While the behavior of the system suggested that the puromycin resistant colonies 
we were obtaining were due to PB transposition events, ie, higher number of colonies 
when mPB-ERT2 was expressed (absence of DOX) and translocated to the nucleus 
(presence of TM), it was important to verify that this was indeed the case, as the whole 
strategy of achieving non-integrative iPSc colonies would depend crucially on whether 
the reprograming cassette had been integrated into the genome by a transposition event 
or not. 
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In order to do this, 12 individual puromycin resistant colonies were individually 
isolated and expanded. Genomic DNA was extracted from 4 lines and we attempted to 
determine what type of integration had occured by scoring for presence or absence of 
different regions of the plasmid originally transfected into the cells by PCR, as shown in 
Fig 10. 
 
Fig. 10. Composed figure of the genomic PCRs performed on the four individual puro-resistant clones (B, 
C, D and E) and the control for each of the PCR primer pairs (A), using 293T HEK genomic DNA. The PCR primer 
pairs are represented with the numbers 1 to 8 and represent PCR1 to PCR8 
In order to score for presence or absence of different regions of the original 
plasmid, primers for 8 PCR products were designed to scan the full length of the 
plasmid. All PCR products were between 300 and 400 bp long. PCR product 1 was 
upstream of the PB 5´TR. PCR products 2, 3, 4, 5 and 6 spanned different regions 
internal to the PB TR's, ie, mapped within the transposon and PCR products 7 and 8 
mapped downstream of the PB 3´TR. 
Results are shown in Fig.11. 
 
Fig. 11. Schematic representation of Eneas with the amplification region of each of the diagnostic primer 
pairs (PCR1 to PCR8)  
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3.2.3. Several points are worth mentioning: 
Despite repeated attempts, we were unable to get a clean negative result using 
genomic DNA from untransfected 293T HEK cells. As can be seen in panel A, PCR 
products 2 and 5 seemed slightly positive, suggesting that early on a contamination of 
ENEAS into non transfected cells occured. Unexpectedly, a strong band corresponding 
to PCR product 8 was evident, suggesting the presence of this plasmid region in the 
original cell line, presumably due to the original manipulations performed on 293T 
HEK cells in order to immortalize them. Of note, PCR product 1 was absent from all 4 
lines tested, while PCR products 2, 3, 4 and 5 (representing sequences internal to the pB 
TRs) were uniformly positive in all 4 lines. PCR product 6, mapping to a CG rich 
sequence in the PuTK region of the transposon did not amplify its product, except for  a 
faint band in clone 3. We surmise that the primers performed poorly to the CG rich 
nature of the target. PCR product number 8, showing a strong band in the negative 
(panel A), was also postive in all four clones and therefore uninformative. PCR product 
6, also mapping to plasmid sequences downtream of the 3´TR, was absent from the 
negative (panel A), but also present in the four clones analyzed. The PCR results 
analyzing the 5´TR end of the construct seem clear: plasmid sequences upstream of the 
5´TR are absent, while PCR products 2, 3, 4 and 5 downstream of the 5´TR (within the 
transposon), are uniformly present in all 4 clones, as would be expected from a 
transposition event. The situation is less clear at the 3´TR end of the construct due to the 
amplification of PCR products 7 and 8, which could be due to a) presence of plasmid 
sequences in the original 293T HEK cells, or b) presence of a background level of 
random integration of plasmid sequences in addition to a transposition event. In sum, 
and though the experiment was not air tight, the results are consistent with integration 
by transposition in a genetic background already containing plasmid sequences. 
3.3. What are the conditions of DOX, TM and duration of pulse 
required to mobilize the transposon integration out of the host genome? 
We then proceeded to attempt to provide our puromycin resistant lines with a 
second pulse of expression of mPB-ERT2 in order to mobilize the transposon out of the 
host genome rendering it resistant to GCV. 
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To do so, a puromycin resistant line was chosen. Cells were seeded and given a 
similar pulse of absence of DOX combined with 1mM tamoxifen for 72 hs. Then DOX 
2 µg/ml was added and TM eliminated from the culture medium to stop further 
transposition. Control cells recieved no expression pulse. Both control and tester cells 
were cultured in presence of GCV. Our expectation was that cells that were puromycin 
resistant would also express TK and therefore be sensitive to GCV, while cells that had 
lost the transposon would be resistant to GCV. Unexpectedly, cells that had not been 
subject to the transposon-mobilization protocol were unaffected by presence of GCV, 
and therefore our negative selection strategy failed to work in this particular experiment. 
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4. Discussion 
One of the first preoccupations in the field of direct reprogramming after its 
discovery in 2006 was how to develop reprogramming technologies that would avoid 
the derivation of iPSc lines harboring exogenous genes or having undergone insertional 
mutagenesis. The initial Yamanaka approach used individual retroviral vectors 
expressing OCT4, SOX2, KLF4 and c-Myc. The resulting iPSc had multiple insertions 
of retroviruses which despite having been silenced in the pluripotent state remained a 
potential problem in terms of potential cell therapy applications. A number of 
approaches were tested by many groups worldwide to reduce the risks associated with 
exogenous gene sequences and insertional mutagenesis. Some of the main approaches 
have been reviewed (see Gonzalez et al— Reprogramming a la carte) are summarized 
below: 
1) In order to reduce the number of insertional mutagenesis events resulting 
from the use of multiple individual retroviral factors, reprograming lentiviral vectors 
were designed carrying polycistronic reprogramming cassettes consisting of several 
reprogramming genes linked by IRES or 2A self-cleaving peptide sequences. This 
approach minimized the risk of insertional mutagenesis to a minimium of one lentiviral 
insertion (ref). 
2) LoxP recombination sites were inserted into the retroviral vectors; once iPSc 
lines were derived, transient expression of CRE recombinase was used to excise the 
reprogramming cassette. This approach eliminated the problem of presence of 
exogenous sequences, but not the problem of insertional mutagenesis. 
3) Non integrative viral vectors were used, such as Sendai Virus or Adenovirus. 
While these approaches were successful, the reprogramming efficiency was exceedingly 
low. 
4) Reprogramming was attempted by expression of transgenes from transiently 
expressed plasmids, under the rationale that perhaps a strong initial reprogramming 
pulse obtained without insertion of reprogramming sequences into the genome would 
suffice. However, this approach had low efficiency in mice and did not work in human 
cells. 
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5) Use of episomal vectors based on the Epstein Bar virus. Plasmids bearing the 
EBNA1 origin of replication and a reprograming cassette are introduced into the cells 
by electroporation and are maintained episomaly. While they are present, they maintain 
a reprogramming pulse, but eventually they are lost, resulting in integration free iPSc. 
6) Use of synthetic mRNA for the reprogramming factors. Messenger RNAs 
specifically synthesized to avoid the PKR response are transfected into cells to achive 
reprogramming. 
7) Transduction of recombinant protein has been reported, but has very low 
efficiency. 
8) Use of the PB transposon: this system involved transfection of two plasmids 
into cells to be reprogrammed. The first plasmid contained a PB transposon carrying a 
reprograming cassette. The second plasmid expressed mPB transposase. This resulted in 
transposition of the reprogramming PB into the genome and derivation of iPSc. In order 
to eliminate the transposon, the PB transposase coding plasmid was re-delivered to the 
iPSc and lines subcloned and tested for loss of the PB transposon by southern. In 
addition, insertion sites were mapped and analyzed to determine if any mutation event 
persisted. 
All of these approaches suffer from being inefficient, laborious and/or expensive. 
Therefore, we set out to design a system that would be simple, efficient and inexpensive, 
and that would result in iPSc lines free of reprogramming factors and insertional 
mutagenesis events. 
We aimed to design a PB based reprograming strategy in which all the elements 
would be in place to a) express the reprogramming genes and b) express the genetic 
elements that control PB transposition by simple manipulations in the culture medium. 
According to the design, the PB transposon would contain 3 elements: 
1) A reprograming cassette 
2) A constitutive promoter driving the tTA transactivator and a PuTK cassette 
and 
3) A DOX inducible promoter driving the piggybac transposase fused to an 
ERT2 nuclear localization domain. 
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Once this plasmid was transiently delivered to the cells, a window of culture 
conditions favoring mPB-ERT2 expression and translocation to the nucleus would 
allow the reprograming transposon to insert into the host genome. Stable expression of 
the reprograming cassette from its genomic locus would result in reprogramming to the 
iPSc state. So far, our system is identical to the method of Yusa et al (2009) in that the 
reprograming cassette is delivered to the genome by use of a piggybac vector. However, 
in the system of Yusa et al, transposase was delivered transiently twice. While the first 
delivery is trivial, the second delivery implies a round of subcloning and 
characterization which is extremely laborious. In our system, two new elements are 
introduced into the design. The first is a PB transposase inducible expression cassette, 
which would allow expression of transposase by simple manipulation of the culture 
medium by addition or elimination of DOX and TM. Manipulation for expression of 
transposase would make induction of transposition into or out of the genome trivial. The 
second element is a negative selection cassette expressing TK. A cell expressing TK 
will be sensitive to GCV. Once iPSc were derived, a second window of transposon 
mobilization would be applied to the cells and clones having lost the transposon would 
be selected for resistance to GCV. 
A first problem is that all the elements required for the strategy do not 
comfortably fit in the PB transposon. The full cargo is around 16 kb, well above th 8 
KB maximum cargo capacity of PB. A modified version of PB has been reported in 
which mutation of the PB TRs and optimization of the transposase codon usage has 
resulted in a system capable of mobilizing up to 18 kb of cargo, but this system is 
proprietary and unavailable to us. Therefore we opted for designing the binary system 
described in this project. We are aware that having two PB transposons introduces 
additional conditions to our system. Ideally we would need to determine the transfection 
parameters that would result in integration of a minimal amount of both transposons, 
ideally only one copy of each. This would require careful titration of the plasmid 
amounts initially transfected into the cells to be reprogrammed. Integration of high 
numbers of transposons would be undesirable, as when PB transposes out of the 
genome it re-integrates into the genome with a frequency of 50%. Therefore, high copy 
numbers would result in no clones surviving the GCV selection. Furthermore, tightness 
of regulation of the transposase by DOX and TM is also a concern, as leaky expression 
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of transposase might result in ongoing transposition events during reprogramming that 
would be mutagenic. 
This thesis describes progress towards developing this system. Initially, the 
construction of the two PB system was one step away from completion. The first 
plasmid (called Remo) had been constructed and consisted of a reprograming cassette 
consisting of OCT4, SOX2, KLF4, c-Myc and GFP driven by a CAG promoter and a 
PuTK cassette driven by a CMV promoter. The second plasmid was partially built and 
required a last cloning step consisting in the insertion of a TRE-CMV-mPB-ERT2 
cassette into a PB backbone already containing a polycistronic construct consisting of a 
tTA transactivator linked to a PuTK cassette driven by a PGK promoter. This cloning 
step was the first task of this thesis. 
We proceeded to test the plasmid. In order to do so, we successfully 
demonstrated that it behaved as expected in terms of DOX regulation of the expression 
of mPB-ERT2. We also demonstrated that by delivering the plasmid into 293T HEK 
cells and manipulating the levels of DOX and TM in the medium, we could obtain 
puromycin resistant lines. The number of puromycin resistant colonies obtained was 
significantly higher when DOX as absent, suggesting that the colonies resulted from 
transposition events. Presence of TM added an extra layer of regulation, albeit weaker. 
Our PCR analysis, while not a clean as would be desired, suggested that transposition 
was indeed occurring, although a background level of random integration could not be 
ruled out. Finally, our attempt to determine whether we could use GVC to select clones 
that had successfully mobilized PB out of the genome was unsuccessful. Unexpectedly, 
293T HEK cells that had been transfected with ENEAS and selected for puromycin 
resistance were insensitive to GCV. We see two possible explanations for this. One 
possibility is that the level of expression of the fusion protein PuTK (driven from a PKG 
promoter) is high enough to result in resistance to puromycin, but too low to result in 
sensitivity to GCV. If so, PGK would have to be replaced by a stronger promoter. The 
second possibility is that the high metabolism of 293T HEK cells renders them 
insensitive to GCV, or that they are insensitive to GCV for other unknown reasons, 
although we have found no report of this in the literature. In this sense, 293T HEK cells 
were a poor choice of cell to work with. The hypothesis of high metabolism could be 
tested by culturing the 293T HEK cells in a less rich medium to slow down their 
metabolism, but is probably not worthwhile, as cell to be reprogrammed would be 
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primary cells such as fibroblasts or keratinocytes. In sum, this thesis has contributed a 
stage in the development of this system. 
Future directions: 
The next step would be to transfect both Remo and Eneas into mouse fibroblasts. 
The total amount of Remo and Eneas would have to be titrated and tested. Too much 
plasmid might result in high levels of transposition and a high number of integrated 
transposon copies. This in turn would result in low efficiency of mobilization of the 
transposon out of the genome. On the other hand, low levels of plasmids would result in 
low reprogramming efficiencies. Another parameter which needs to be investigated 
would be the relative ratio of Remo to Eneas. The objective would be to find the ratio of 
Remo and Eneas that provides the minimum amount of Remo required for 
reprogramming and the minimum amount of Eneas that provides regulable expression 
of mPB-ERT2. iPSc lines would need to be derived, expanded, subjected to a second 
transposon mobilization pulse and selected with GCV. Finally, the resulting iPSc lines 
would need to be characterized in terms of pluripotency, differentiation, karyotipic 
integrity and most importantly, absence of plasmid sequences and mutagenic events. 
. 
. 
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